迅速診断市場：製品別、用途別-2025～2030年の世界予測

迅速診断市場の2023年の市場規模は304億2,000万米ドルで、2024年には340億3,000万米ドルに達すると予測され、CAGR 11.95%で成長し、2030年には670億5,000万米ドルに達すると予測されています。

迅速診断市場は医療産業に不可欠なサブセットであり、患者の治療成果を大幅に改善する迅速で正確な診断結果を提供することに重点を置いています。この市場には、ラテラルフロー免疫測定法、ポイントオブケア検査キット、分子診断装置などの技術や製品が含まれ、それぞれが臨床現場でのタイムリーな意思決定を可能にしています。迅速診断システムの必要性は、結果を即座に提供する能力にあり、患者の待ち時間を短縮し、迅速な治療介入を促進します。これらの技術は、COVID-19のような感染症の大流行や、心血管疾患や呼吸器疾患のような緊急診断が必要な疾患の管理において極めて重要です。主要エンドユーザーには、病院、臨床検査室、在宅医療の現場、研究機関などがあります。

迅速診断の市場成長は、ポイントオブケア検査需要の高まり、感染症流行の増加、個別化医療へのシフトの影響を受けています。さらに、技術の進歩や診断プロセスにおける人工知能の統合は、急成長の機会を提供しています。企業は、よりポータブルでコスト効率が高く、使いやすい診断ツールを開発するための研究開発に投資することで、こうした動向を活用することができます。複数の病態を同時に検査するマルチプレックスアッセイの開発も戦略的方向性の一つです。しかし、規制上のハードル、高コスト、一部の迅速検査法の精度の限界といった課題が、成長の限界となっています。さらに、低リソース環境での市場拡大は、強固な医療インフラの必要性によって阻害されています。

イノベーションは、診断精度の向上、コスト削減、デジタルヘルスソリューションの導入、サプライチェーン・ロジスティクスの改善に焦点を当て、広く利用できるようにする必要があります。データ分析と意思決定支援システムを提供するスマート診断薬を開発するためのハイテク企業とのコラボレーションは、市場優位性の新たな領域を提示することができます。競合情勢は技術進歩に牽引されており、市場との関連性を維持するためには継続的なイノベーションが必要であることを示唆しています。製品のイノベーションとコストや精度の制約とのバランスをうまくとることができる企業は、この進化する市場で成功を収める可能性が高いです。

市場力学：急速に進化する迅速診断市場の主要市場洞察を公開

迅速診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症の流行拡大
  • 対象疾患の罹患率の増加
  • 政府の支援ポリシー
  • 早期診断に関する意識の高まりに伴う、分散型環境での迅速診断検査に対する需要の高まり
• 市場抑制要因
  • 新しい迅速診断検査に対する認識不足
• 市場機会
  • 診断、患者管理、疫学、スクリーニングへの採用拡大
  • ベッドサイドでの診断検査に対する需要の高まり
  • 迅速診断製品開発への投資と資金調達の増加
• 市場課題
  • 決定的な中央検査室手法との整合性の欠如

ポーターのファイブフォース：迅速診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：迅速診断市場における外部からの影響の把握

外部マクロ環境要因は、迅速診断市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：迅速診断市場における競合情勢の把握

迅速診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：迅速診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、迅速診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：迅速診断市場における成功への道筋を描く

迅速診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の蔓延拡大
    • 対象疾患の発生率増加
    • 政府の支援ポリシー
    • 早期診断に対する意識の高まりとともに、分散環境における迅速な診断検査の需要が高まっている
  • 抑制要因
    • 新しい迅速診断検査に関する認識不足
  • 機会
    • 診断、患者管理、疫学、スクリーニングへの採用が増加
    • ベッドサイド診断検査の需要増加
    • 迅速な診断製品開発への投資と資金の増加
  • 課題
    • 決定的な中央研究所の方法との整合性の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 迅速診断市場：製品別

• イントロダクション
• OTC迅速診断検査
• プロフェッショナル向け迅速診断検査

第7章 迅速診断市場：用途別

• イントロダクション
• 血糖値迅速診断
• 心臓代謝迅速診断
• 凝固迅速診断
• 便潜血迅速診断
• 感染症迅速診断
• 妊娠と不妊迅速診断
• 毒物迅速診断

第8章 南北アメリカの迅速診断市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の迅速診断市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの迅速診断市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Abingdon Health Group
• ACON Laboratories, Inc.
• AgaMatrix, Inc.
• Arbor Vita Corporation
• Assure Tech.（Hangzhou）Co., Ltd.
• BioMedomics Inc.
• Biomerica
• bioMerieux S.A.
• Biopanda Reagents Ltd.
• Cellex Incorporated
• Chembio Diagnostics, Inc.
• Clinical Reference Laboratory, Inc.
• EKF DIAGNOSTICS HOLDINGS PLC
• F. Hoffmann-La Roche Ltd.
• Healgen Scientific LLC
• Meridian Bioscience, Inc.
• Sekisui Diagnostics Group
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. RAPID DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. RAPID DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RAPID DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RAPID DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY OTC RAPID DIAGNOSTICS TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL RAPID DIAGNOSTICS TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD GLUCOSE RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOMETABOLIC RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY FECAL OCCULT BLOOD RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TOXICOLOGY RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. ITALY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. ITALY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. POLAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. POLAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. QATAR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. QATAR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 105. RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Rapid Diagnostics Market was valued at USD 30.42 billion in 2023, expected to reach USD 34.03 billion in 2024, and is projected to grow at a CAGR of 11.95%, to USD 67.05 billion by 2030.

The rapid diagnostics market is an essential subset of the healthcare industry, focused on providing quick and accurate diagnostic results that significantly improve patient care outcomes. This market includes technologies and products like lateral flow immunoassays, point-of-care testing kits, and molecular diagnostics devices, each enabling timely decision-making in clinical settings. The necessity of rapid diagnostic systems lies in their ability to deliver immediate results, reducing patient wait times and facilitating faster treatment interventions. These technologies have been pivotal in managing infectious disease outbreaks, like COVID-19, and other conditions requiring urgent diagnosis, such as cardiovascular and respiratory diseases. The primary end-users include hospitals, clinical laboratories, home care settings, and research institutions.

Market growth in rapid diagnostics is influenced by the rising demand for point-of-care testing, increased prevalence of infectious diseases, and a shift toward personalized medicine. Additionally, technological advancements and the integration of artificial intelligence in diagnostic processes offer burgeoning opportunities. Companies can leverage these trends by investing in research and development to create more portable, cost-effective, and user-friendly diagnostic tools. Developing multiplex assays to test for multiple conditions simultaneously is another strategic direction. However, challenges such as regulatory hurdles, high costs, and the limited accuracy of some rapid testing methods pose limitations to growth. Furthermore, market expansion in low-resource settings is impeded by the need for robust healthcare infrastructures.

Innovation should focus on enhancing diagnostic accuracy, reducing costs, incorporating digital health solutions, and improving supply chain logistics to ensure widespread accessibility. Collaboration with tech companies to develop smart diagnostics that provide data analytics and decision support systems can present new areas of market advantage. The nature of the rapid diagnostics market suggests a competitive landscape driven by technological advancements, underscoring the necessity for continuous innovation to maintain market relevance. Businesses that can successfully balance product innovation with cost and accuracy constraints will likely thrive in this evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rapid Diagnostics Market

The Rapid Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of infectious diseases
  • Increasing incidence of target conditions
  • Supportive government policies
  • Rising demand for rapid diagnostic tests in decentralized settings along with rising awareness regarding early diagnosis
• Market Restraints
  • Lack of awareness regarding newer rapid diagnostic tests
• Market Opportunities
  • Growing adoption for diagnosis, patient management, epidemiology, and screening
  • Increased demand for bedside diagnostic testings
  • Growing investments and funding for rapid diagnostic product development
• Market Challenges
  • Lack of alignment with definitive central lab methods

Porter's Five Forces: A Strategic Tool for Navigating the Rapid Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rapid Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rapid Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rapid Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rapid Diagnostics Market

A detailed market share analysis in the Rapid Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rapid Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rapid Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rapid Diagnostics Market

A strategic analysis of the Rapid Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rapid Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abingdon Health Group, ACON Laboratories, Inc., AgaMatrix, Inc., Arbor Vita Corporation, Assure Tech.(Hangzhou) Co., Ltd., BioMedomics Inc., Biomerica, bioMerieux S.A., Biopanda Reagents Ltd., Cellex Incorporated, Chembio Diagnostics, Inc., Clinical Reference Laboratory, Inc., EKF DIAGNOSTICS HOLDINGS PLC, F. Hoffmann-La Roche Ltd., Healgen Scientific LLC, Meridian Bioscience, Inc., Sekisui Diagnostics Group, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rapid Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across OTC Rapid Diagnostics Test and Professional Rapid Diagnostics Test.
• Based on Application, market is studied across Blood Glucose Rapid Diagnostics, Cardiometabolic Rapid Diagnostics, Coagulation Rapid Diagnostics, Fecal Occult Blood Rapid Diagnostics, Infectious Diseases Rapid Diagnostics, Pregnancy & Fertility Rapid Diagnostics, and Toxicology Rapid Diagnostics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of infectious diseases
    • 5.1.1.2. Increasing incidence of target conditions
    • 5.1.1.3. Supportive government policies
    • 5.1.1.4. Rising demand for rapid diagnostic tests in decentralized settings along with rising awareness regarding early diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of awareness regarding newer rapid diagnostic tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing adoption for diagnosis, patient management, epidemiology, and screening
    • 5.1.3.2. Increased demand for bedside diagnostic testings
    • 5.1.3.3. Growing investments and funding for rapid diagnostic product development
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of alignment with definitive central lab methods
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Rapid Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. OTC Rapid Diagnostics Test
• 6.3. Professional Rapid Diagnostics Test

7. Rapid Diagnostics Market, by Application

• 7.1. Introduction
• 7.2. Blood Glucose Rapid Diagnostics
• 7.3. Cardiometabolic Rapid Diagnostics
• 7.4. Coagulation Rapid Diagnostics
• 7.5. Fecal Occult Blood Rapid Diagnostics
• 7.6. Infectious Diseases Rapid Diagnostics
• 7.7. Pregnancy & Fertility Rapid Diagnostics
• 7.8. Toxicology Rapid Diagnostics

8. Americas Rapid Diagnostics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Rapid Diagnostics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Rapid Diagnostics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Abingdon Health Group
• 3. ACON Laboratories, Inc.
• 4. AgaMatrix, Inc.
• 5. Arbor Vita Corporation
• 6. Assure Tech.(Hangzhou) Co., Ltd.
• 7. BioMedomics Inc.
• 8. Biomerica
• 9. bioMerieux S.A.
• 10. Biopanda Reagents Ltd.
• 11. Cellex Incorporated
• 12. Chembio Diagnostics, Inc.
• 13. Clinical Reference Laboratory, Inc.
• 14. EKF DIAGNOSTICS HOLDINGS PLC
• 15. F. Hoffmann-La Roche Ltd.
• 16. Healgen Scientific LLC
• 17. Meridian Bioscience, Inc.
• 18. Sekisui Diagnostics Group
• 19. Thermo Fisher Scientific Inc.